ArticlePLoS neglected tropical diseases2025
Inter-epidemic seroprevalence of Rift Valley fever virus and associated risk factors in humans in Eastern Rwanda.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigation and response to rift valley fever outbreak in ruminant livestock from Ngoma District, eastern province of Rwanda, 2024.One health (Amsterdam, Netherlands) · 2026Article
- Research progress on the diagnostic techniques and vaccine development of bovine herpesvirus types 1.Frontiers in veterinary science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRift Valley fever (RVF) is a mosquito-borne zoonosis that causes periodic and explosive epizootics/epidemics in Africa and the Arabian Peninsula. In Rwanda, RVF virus (RVFV) circulation has resulted into two major outbreaks in 2018 and 2022, both of which involving humans. Information on the magnitude of human exposure to RVFV in the country is scarce. This cross-sectional study aimed to investigate the seroprevalence of RVFV and associated risk factors in humans in the Eastern province of Rwanda, 3 years after the end of the 2018 outbreak. METHODOLOGY: A total of 552 outpatients at health facilities in five districts of the Eastern province were randomly sampled and interviewed between December 2021 and February 2022. Exposure to RVFV was examined by detection of anti-RVFV IgG/IgM antibodies in serum samples using a competitive enzyme linked immunosorbent assay (c-ELISA). Bivariate and multivariate logistic regressions were used to assess the association between risk factors and RVFV seropositivity.
resultsThe findings revealed an overall seroprevalence of 9.6%. The highest seropositivity, but without significant difference, was observed in Bugesera district (12.9%), followed by Kayonza, (10.8%), Kirehe (8.6%), Rwamagana (7.0%) and Ngoma (6.8%). Odds of seropositivity were significantly higher in people with a history of slaughtering animals (OR 2.26, 95% CI 1.04 - 4.91, p = 0.03), and milking (OR 2.60, 95% CI 1.23 - 5.49, p = 0.012). Sex and age-related differences were not significant.
conclusionThis study is a first serological survey of RVFV spillover to humans in the country and shows that rural communities in Rwanda have been exposed to RVFV. These findings suggest the Eastern province of Rwanda as a potential hotspot for RVFV circulation, and emphasize the need for a countrywide One Health-based surveillance, prevention, and control strategy to minimize the effects of RVFV in the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.